Biomedical Output Surged by 30% to 5.2 Billion in H1

According to related TEDA authorities, the industrial output of local biomedicine industry surged 30% y-o-y to 5.2 billion yuan in the first half of 2009.

Biomedicine is a sunrise industry of the 21st century marked by most enviable profit margin. Tianjin, as one of China's biomedicine base cities, has witnessed record growth in its hi-tech industries over the past years. In particular, biomedicine, as one of TEDA's main economic drivers, demonstrates strong vitality and bright prospects. So far, TEDA is home to four state-level biomedicine R&D centers, five enterprise-owned technology centers, and 12 enterprise-owned engineering centers. In addition, it is also responsible for the planning and construction of China's International Biotechnology and Medicine Innovation Park and Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The later has been completed and will become available this June. Among the 22 start-up projects it has accommodated so far, one has finished phase-III clinical test, another one is in the middle of phase-I clinical test, and most of the rest are developing successfully.

Friendly investment climate guarantees the strong growth and competitiveness of local biomedical players. Novo Nordisk is building its world's largest insulin formulation and filling plant here. Novozymes plans to build its TEDA plant into the No.1 enzymes production center in the Asia-Pacific Region. Both of them are pacesetters in China within their respective industries. Currently TEDA is working intensively on the one-square-kilometer Beijing-Tianjin-Hebei Biomedicine commercialization Demonstration Park. Professional biomedical factory buildings will be put into use by the end of this month.